AU6209700A - Method and compositions for inhibiting biosynthesis or bioactivity of endogenoussteroid sex hormones in humans - Google Patents

Method and compositions for inhibiting biosynthesis or bioactivity of endogenoussteroid sex hormones in humans

Info

Publication number
AU6209700A
AU6209700A AU62097/00A AU6209700A AU6209700A AU 6209700 A AU6209700 A AU 6209700A AU 62097/00 A AU62097/00 A AU 62097/00A AU 6209700 A AU6209700 A AU 6209700A AU 6209700 A AU6209700 A AU 6209700A
Authority
AU
Australia
Prior art keywords
endogenoussteroid
bioactivity
humans
compositions
sex hormones
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU62097/00A
Inventor
Claude L. Hughes Jr.
Denis A. Magoffin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of AU6209700A publication Critical patent/AU6209700A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU62097/00A 1999-07-13 2000-07-12 Method and compositions for inhibiting biosynthesis or bioactivity of endogenoussteroid sex hormones in humans Abandoned AU6209700A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35300499A 1999-07-13 1999-07-13
US09353004 1999-07-13
PCT/US2000/018909 WO2001003687A2 (en) 1999-07-13 2000-07-12 Method and compositions for inhibiting biosynthesis or bioactivity of endogenous steroid sex hormones in humans

Publications (1)

Publication Number Publication Date
AU6209700A true AU6209700A (en) 2001-01-30

Family

ID=23387341

Family Applications (1)

Application Number Title Priority Date Filing Date
AU62097/00A Abandoned AU6209700A (en) 1999-07-13 2000-07-12 Method and compositions for inhibiting biosynthesis or bioactivity of endogenoussteroid sex hormones in humans

Country Status (2)

Country Link
AU (1) AU6209700A (en)
WO (1) WO2001003687A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1190630A1 (en) * 2000-09-22 2002-03-27 Unilever N.V. Use of prenylated flavones
AU770436B2 (en) 2000-09-22 2004-02-19 Unilever Plc Use of prenylated flavones
AU2002240949A1 (en) * 2001-03-21 2002-10-03 Schering Aktiengesellschaft Pharmaceutical combined preparations containing aromatase inhibitors and substances having an estrogen effect in addition to the use thereof for producing a medicament for estrogen-replacement-therapy
WO2002076241A1 (en) * 2001-03-23 2002-10-03 N.V. Nutricia Preparation for the prevention and/or treatment of altered bone metabolism
US7736677B2 (en) * 2001-06-20 2010-06-15 Metaproteomics, Llc Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment
US7361478B2 (en) 2001-11-20 2008-04-22 Allergan, Inc. High-throughput screen for identifying selective persistent sodium channels channel blockers
EP1360959A1 (en) * 2002-05-10 2003-11-12 Schering Aktiengesellschaft Use of 8-prenylflavanones for anti-angiogenesis therapy and for fibrinolytic therapy
WO2003100092A2 (en) * 2002-05-28 2003-12-04 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of cyp11a1 for neurodegenerative diseases
FI20021184A (en) * 2002-06-19 2003-12-20 Hormos Nutraceutical Oy Ltd Lignaanivalmisteita
EP1618875B1 (en) * 2003-04-08 2008-09-10 Kirin Beer Kabushiki Kaisha Composition for inhibition or prevention of bone density lowering
DE102007029042A1 (en) * 2007-06-21 2008-12-24 Analyticon Discovery Gmbh Pharmaceutical composition containing a trihydroxychromenone derivative
WO2009003838A2 (en) * 2007-07-05 2009-01-08 Unilever N.V. Composition comprising polyphenol
WO2009003832A2 (en) * 2007-07-05 2009-01-08 Unilever N.V. Composition comprising polyphenol
EP2025335A1 (en) * 2007-08-16 2009-02-18 InterMed Discovery GmbH Extracts with liver-X-receptor modulators, compounds and their use in weight control and treatment of disorders of lipid metabolism
FR2940123B1 (en) * 2008-12-22 2011-04-22 Granions Lab Des ASSOCIATION OF COMPOUNDS FOR THE TREATMENT OR PREVENTION OF HEAT BURSTS AND SUES BEEN GENERATED BY THE MENOPAUSE
JP2012092138A (en) * 2011-12-27 2012-05-17 Maruzen Pharmaceut Co Ltd Skin cosmetic and hair cosmetic
JP5668001B2 (en) * 2012-03-05 2015-02-12 丸善製薬株式会社 Skin cosmetics and hair cosmetics
US20140023618A1 (en) * 2012-07-23 2014-01-23 Applied Biology Systems and methods for treatment of androgenetic skin conditions by microbial organisms
CN106404955B (en) * 2016-09-10 2019-12-17 长治医学院 Method for determining content of quercetin-7-glucoside in sorghum red pigment
CN106822091A (en) * 2017-02-14 2017-06-13 天津中医药大学 Purposes of the Kaempferol in preparing for preventing and/or treating the medicine by the too high disease for causing of testosterone levels
IT201700027628A1 (en) * 2017-03-13 2018-09-13 Neilos S R L COMPOSITION FOR USE IN REDUCING PELI GROWTH
KR102020722B1 (en) * 2018-02-28 2019-09-11 전북대학교산학협력단 A composition comprising a combination of flavonoid and iridoid compound for treating and preventing androgen deficiency and PADAM syndrome
CN114984126A (en) * 2022-07-15 2022-09-02 深圳德荫堂生物科技有限公司 Biological agent suitable for supplementing hormone for female and production method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5523087A (en) * 1995-02-15 1996-06-04 Bio-Virus Research Incorporated Pharmaceutical compositions for the treatment of diabetic male sexual dysfunction
WO1998021946A1 (en) * 1996-11-18 1998-05-28 Internutria, Inc. Composition and treatment for persistent reproductive transition symptoms

Also Published As

Publication number Publication date
WO2001003687A3 (en) 2001-08-09
WO2001003687A2 (en) 2001-01-18

Similar Documents

Publication Publication Date Title
AU6209700A (en) Method and compositions for inhibiting biosynthesis or bioactivity of endogenoussteroid sex hormones in humans
AU2001280922A1 (en) Bioactive coating compositions and methods
AU2001233526A1 (en) Stent delivery system and method of use
AU2001281344A1 (en) Angulated stent delivery system and method of use
AU4904601A (en) Stent and stent delivery assembly and method of use
AU4205100A (en) Methods and compositions for the treatment of pancreatitis
AU2001268749A1 (en) Orthopedic implant and method of making metal articles
AU2609901A (en) Antimicrobial compositions and methods of use
AUPR510001A0 (en) Formulation and method
HUP0105160A3 (en) Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-betha-cyclodextrin or 2-hydroxypropyl-betha-cyclodextrin and method for its preparation and pharmaceutical compositions containing them
AU2001286651A1 (en) Microparticle composition and method
AUPQ196799A0 (en) Method of preservation of amnion and uses thereof
AU2001271031A1 (en) Cosmetic compositions for reducing and method of using the same
AU2001288395A1 (en) Method for enhanced delivery of oxybutynin and compositions thereof
EP1578348A3 (en) Formulation comprising bioactive agents and method of using same
AU2002367925A1 (en) Composition and method for minimizing or avoiding adverse effects of vesicants
AU2002303552A1 (en) Methods and compositions for prevention of angioproliferation
AU2002364911A1 (en) Dmt-tic di- and tri-peptidic derivatives and related compositions and methods of use
AU2002245510A1 (en) Method and composition for embalming
AU4839100A (en) Methods of using and compositions comprising n-desmethylzolpidem
AU2002320244A1 (en) Method and composition for prolonging the residence time of drugs in the gut
AU1943501A (en) Methods of treating inflammation and compositions therefor
AUPQ876400A0 (en) Compositions and method of using them
AU6733100A (en) Antiallergen compositions and method of inactivating allergen
AU2002246221A1 (en) Method and composition

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase